We have followed, at 3, 6, 12, 24 months after the onset of therapy, 584 patients with refractory Generalized and Partial Epilepsy, started on LTG as add-on. Drop-out accounted for 32% of the SGE patients, 23% of the CGE, 13% IGE, and 40% EP. Lack of efficacy and side effect accounted for 71% and 29% respectively of drop-out rate. Most frequent adverse events were skin rashes and psychological disturbances.
|Translated title of the contribution||Lamotrigine triveneto study: Reasons for discontinuance of therapy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Oct 2002|
ASJC Scopus subject areas
- Clinical Neurology